NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...
The comments come as Sanofi reported Thursday that its total vaccine sales fell 2.5% in the fourth quarter and 1.2% for the ...
As Maryland moves toward price limits on certain prescription drugs, patients continue searching for affordable options at the pharmacy.
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its fourth-quarter 2025 investor letter for the “Baird Chautauqua International and ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
By Bhanvi Satija LONDON, Jan 29 (Reuters) - French drugmaker Sanofi said on Thursday it expects sales to grow by a ...
The French drugmaker on Thursday reported sales of 11.30 billion euros for the period, up 13% on year at constant currency.
New research suggests pain is not a simple signal of injury but a process that unfolds across nerves, spinal cord, and brain.
Clinical Trials Arena on MSN
Sanofi’s Dupixent successor heads to regulators after Phase III success
The pharma will vie for amlitelimab’s approval, despite the COAST 2 trial missing a co-primary endpoint.
4hon MSN
Beyond the brand names: Everything you need to know about Ozempic and other GPL-1 medications
Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 ...
A better approach? Support the systems that regulate them naturally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results